Product Description: Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC[1][2][3][4][5][6][7].
Applications: COVID-19-immunoregulation
Formula: C40H68O11
Citations: Aging (Albany NY). 2021 Aug 25;13(16):20534-20551./Am J Chin Med. 2020;48(7):1693-1713./Bioact Mater. 20 July 2022./Biochem Biophys Res Commun. 2020 May 7;525(3):759-766./Biochem Pharmacol. 2022 Jan 31;198:114938./Biochem Pharmacol. 2023 May 15, 115599./Biochim Biophys Acta Mol Cell Res. 2024 Feb 15:119689./Biomaterials. 2022 Nov 12;291:121888./Biomaterials. 2024 Jan 5:305:122466./Biomed Pharmacother. 2022 Jul;151:113098./bioRxiv. 2024 September 07./Biosci Biotechnol Biochem. 2024 May 8:zbae058./Brain Behav. 2020 Jun;10(6):e01627./Cancer Sci. 2024 Apr 13./Cell Biol Toxicol. 2021 Oct 12./Cell Commun Signal. 2024 Nov 25;22(1):565./Cell Commun Signal. 2025 Jan 6;23(1):6./Cell Death Differ. 2021 Sep 11./Cell Death Dis. 2022 Apr 19;13(4):372./Cell Death Dis. 2024 Jan 18;15(1):66./Cell Death Dis. 2020 Feb 18;11(2):132. /Cell Death Discov. 2021 Feb 10;7(1):31./Cell Host Microbe. 2023 Nov 8;31(11):1820-1836.e10./Cell Metab. 2020 May 5;31(5):892-908.e11./Cell Microbiol. 2022./Cell Rep. 2024 Dec 12;43(12):115065./Cell Res. 2023 Sep 19./Chem Biol Interact. 2024 Oct 8:111262./Chin J Integr Med. 2022 Nov 19./Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105./Clin Transl Med. 2024 Mar;14(3):e1623./Ecotoxicol Environ Saf. 2022 Dec 9;249:114359./Environ Toxicol. 2023 Mar 29./Exp Ther Med. 2021 Oct;22(4):1046./Fish Shellfish Immunol. 2024 Aug 13:109837./Front Immunol. 2021 Jul 7;12:688674./Genes Dis. 20 June 2022./Immun Inflamm Dis. 2023 Oct; 11(10): e1043./Inflamm Res. 2024 Sep 18./Inflamm Res. 2024 Sep 28./Int Immunopharmacol. 2021 Jan 7;92:107352./Int Immunopharmacol. 2022 Aug 6;111:109098./Int Immunopharmacol. 2022 Oct 14;113(Pt A):109321./Int Immunopharmacol. 2023 May 12;120:110292./Int Immunopharmacol. 2024 Dec 9:145:113781./Int Immunopharmacol. 2024 Feb 16:130:111649./Int J Biol Sci. 2024 Jan 1;20(2):733-750./Int J Med Sci. 2020 Jun 29;17(11):1652-1664./J Am Heart Assoc. 2022 Jul 5;11(13):e025266./J Cardiothorac Surg. 2024 May 10;19(1):283./J Cell Mol Med. 2020 Jul;24(14):8078-8090./J Cell Mol Med. 2021 Nov;25(21):10268-10278./J Ethnopharmacol. 2021 Sep 30;114694./J Extracell Vesicles. 2023 Feb;12(2):e12310./J Med Chem. 2024 Sep 20./J Nanobiotechnology. 2023 Aug 14;21(1):269./J Neuroinflammation. 2021 Jun 24;18(1):142./J Ovarian Res. 2024 Nov 26;17(1):236./J Pharm Pharmacol. 2024 Jan 12:rgad113./J Toxicol Sci. 2023;48(3):139-148./J Virol. 2023 Nov 27:e0133823./Life Sci. 2023 Oct 17:122176./Metab Brain Dis. 2022 Mar 10./Mol Immunol. 2023 Jan 12;155:7-16./Mol Immunol. 2024 Jan 23:166:79-86./Mol Neurobiol. 2021 Sep 25./Oxid Med Cell Longev. 2022 Feb 7;2022:9030771./PeerJ. 2023 Feb 13;11:e14826./PeerJ. October 4, 2022./Pharm Biol. 2022 Dec;60(1):535-542./Phytomedicine. 2023 Mar 5;113:154743./Phytother Res. 2021 Mar 3./PLoS Pathog. 2024 Jul 22;20(7):e1012398./Prostaglandins Other Lipid Mediat. 2024 Sep 9:106904./Research Square Preprint. 2023 Apr 12./Research Square Preprint. 2024 Feb 12./Shock. 2023 May 2./Ther Adv Med Oncol. 2021 Jan 21./Tissue Cell. 2024 Oct 20:91:102588./Tissue Eng Regen Med. 2024 Jul 26./Viruses. 2022, 14(8), 1734./Acta Pharmacol Sin. 2021 Sep 24;1-8./Acupunct Herb Med. 2024 Nov 12./Appl Microbiol Biotechnol. 2017 May;101(10):4201-4213./Biomed Pharmacother. 2024 Jul 12:177:117121./Brain Res. 2024 Jul 10:149121./Brain Res. 2024 May 1:148975./Cancer Lett. 2024 Mar 8:216797./Cell Death Differ. 2022 May 14./Cell Death Dis. 2021 Dec 14;12(12):1159./Cell Rep. 2019 May. /CNS Neurosci Ther. 2021 Dec 23./Crit Care. 2021 Oct 12;25(1):356./Eur J Med Chem. 2023 Jan 5;245(Pt 2):114919./Front Microbiol. 2020 Apr 30;11:790./Inflammation. 2021 Jan 6./Inflammation. 2024 Mar 18./Int Immunopharmacol. 2024 Jun 7:136:112346./Int J Mol Med. 2021 Dec;48(6):219./iScience. 21 September 2021./J Agric Food Chem. 2024 Jun 10./J Am Chem Soc. 2022 Oct 13./J Biol Chem. 2021 Dec 22;101532./J Ethnopharmacol. 2024 Aug 17:118661./J Exp Med. 2022 Oct 3;219(10):e20212117./J Exp Med. 2023 Mar 6;220(3):e20221316./J Funct Foods. 2023, 100: 105386./J Funct Foods. December 2020, 104274./J Gastroenterol. 2024 Jun 12./J Hazard Mater. 2022 May 10;436:129093./J Neuroinflammation. 2022 Sep 28;19(1):237./J Pharm Pharmacol. 2024 Jul 10:rgae077./Life Sci. 2021 Jul 21;282:119814./Metab Brain Dis. 2022 Feb;37(2):329-341./Mol Cell Biochem. 2023 Mar 29./Mol Immunol. 2020 Apr 13;122:28-37./Molecules. 2022 Apr 12;27(8):2488./Oncotarget. 2018 Jan 13;9(13):10868-10879. /Oxid Med Cell Longev. 2023 Jan 12;2023:3317307./Parasit Vectors. 2022 Sep 23;15(1):334./Phytomedicine. 2023 Jun 10, 154922./Phytomedicine. 2024 May 28:131:155758./Research Square Preprint. 2021 Jul./Research Square Preprint. 2023 Aug 31./Research Square Preprint. 2024 Aug 26./Sensor Actuat B-Chem. 297 (2019) 126801./Signal Transduct Target Ther. 2024 Dec 30;9(1):367./SSRN. 2023 Oct 30./Transl Res. 2022 Apr 20;S1931-5244(22)00073-1./World J Tradit Chin Med. 2024 Apr 12.
References: [1]Zotova L, et al. Novel components of an active mitochondrial K(+)/H(+) exchange. J Biol Chem. 2010 May 7;285(19):14399-414./[2]Mariathasan S, et al.Cryopyrin activates the inflammasome in response to toxins and ATP.Nature. 2006 Mar 9;440(7081):228-32./[3]Bissinger R, et al. Triggering of Suicidal Erythrocyte Death by the Antibiotic Ionophore Nigericin. Basic Clin Pharmacol Toxicol. 2016 May;118(5):381-9./[4]Xiaoli Zhu, et al. Nigericin is effective against multidrug resistant gram-positive bacteria, persisters, and biofilms. Front Cell Infect Microbiol. 2022 Dec 20:12:1055929./[5]Guanzhuang Gao, et al. Evidence of nigericin as a potential therapeutic candidate for cancers: A review. Biomed Pharmacother. 2021 May:137:111262./[6]Lisha Wu, et al. Nigericin Boosts Anti-Tumor Immune Response via Inducing Pyroptosis in Triple-Negative Breast Cancer. Cancers (Basel). 2023 Jun 16;15(12):3221./[7]Juan Sebastian Yakisich, et al. Nigericin decreases the viability of multidrug-resistant cancer cells and lung tumorspheres and potentiates the effects of cardiac glycosides. Tumour Biol.2017 Mar;39(3):1010428317694310.
CAS Number: 28380-24-7
Molecular Weight: 724.96
Compound Purity: 99.37
Research Area: Cancer; Infection
Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C)/Ethanol : ≥ 33.33 mg/mL
Target: Antibiotic;Bacterial;NOD-like Receptor (NLR);Potassium Channel;Pyroptosis;Wnt;β-catenin
English
Deutsch
